Does intermittent repeated levosimendan infusions reduce hospital readmissions and improve survival in patients with advanced heart failure?
Intermittent levosimendan in advanced heart failure significantly improved 12-month survival and reduced early decompensation or death, despite a non-significant reduction in overall hospital readmissions.
In our study, intermittent levosimendan in patients with AdHF produced a statistically non-significant reduction in the incidence of hospital readmissions for acute decompensated HF, a significantly lower cumulative incidence of acute decompensation of HF and/or death at 1 and 3 month of treatment and a significant improvement in survival during 12 months of treatment.
García‐González et al. (Sat,) studied this question.